Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Novelos Therapeutics Inc NVLT

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Opinion & Analysis (GREY:NVLT)

No current opinion is available.

Bullboard Posts (GREY:NVLT)

is it new ?

http://biz.yahoo.com/e/090218/nvlt.ob8-k.html
antisoma69 - February 19, 2010

Novelos' cancer compound may revolutionize cancer

http://www.stockhouse.com/News/USReleasesDetail.aspx?n=7571346Novelos' cancer compound may revolutionize cancer treatments in...
Bixbyte - December 23, 2009

NOV-002 A Cancer Breakthrough Medication

NOV-002, a proprietary formulation of oxidized glutathione, is the lead compound of Novelos Therapeutics Inc (NVLT). NOV-002 acts as a...
Bixbyte - December 21, 2009

Cure for Cancer on FOX News MIAMI TV 7

Lilian Mills of Miami Florida her breast cancer was cured made the Channel 7 FOX news story on Television. http://www.wsvn.com...
Bixbyte - December 11, 2009

RE: BYE BYE SHORTERS MAJOR DRUG DEAL

Added to my position today. For insightful reasons to like NVLT, please read Bixbite's comments. My reasons are intuitive. NVLT...
risky_ventura - January 23, 2008

BYE BYE SHORTERS MAJOR DRUG DEAL

Novelos Therapeutics and Lee's Pharmaceutical Sign Exclusive Collaboration Agreement in China for Novelos' Cancer and Hepatitis...
Bixbyte - December 17, 2007